Breakwater Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Breakwater Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9	Closed	-$488	–	515
2025 Q3	$488	Hold	9	–	–	﹤0.01%	452
2025 Q2	$495	Hold	9	–	–	﹤0.01%	296
2025 Q1	$637	Hold	9	–	–	﹤0.01%	295
2024 Q4	$592	Hold	9	–	–	﹤0.01%	293
2024 Q3	$633	Hold	9	–	–	﹤0.01%	289
2024 Q2	$741	Hold	9	–	–	﹤0.01%	291
2024 Q1	$787	Buy	+9	New	+$806	﹤0.01%	284

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Breakwater Investment Management's BMRN Position: Q4 2025 in Review

Breakwater Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 9 shares — an estimated $488 sold.

Breakwater Investment Management first reported a position in BMRN in Q1 2024 and held it in 7 quarters. The position peaked at $787 in Q1 2024. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Breakwater Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Breakwater Investment Management sold 9 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $488.
Breakwater Investment Management first reported a position in BioMarin Pharmaceuticals in Q1 2024 and held it in 7 quarters.
Breakwater Investment Management's BioMarin Pharmaceuticals position peaked at $787 in Q1 2024.
540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Breakwater Investment Management's 13F filing for Q4 2025, filed 2 Feb 2026.